Voyager (VYGR) Exercises Options to Use REGENXBIO’s (RGNX) NAV Vectors

November 29, 2016 8:05 AM EST
Get Alerts VYGR Hot Sheet
Trade VYGR Now!
Join SI Premium – FREE

Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.

Voyager Therapeutics, Inc. (Nasdaq: VYGR) and REGENXBIO Inc. (Nasdaq: RGNX) announced that Voyager has exercised commercial options for the use of REGENXBIO’s NAV vectors for the development and commercialization of gene therapies for specific neurological diseases.

Upon exercise of the options, REGENXBIO has granted Voyager a non-exclusive worldwide commercial license, with rights to sublicense, to three specific NAV vector sequences covered by REGENXBIO’s NAV Technology Platform, each for the treatment of a specific neurological disease. In return for these rights, REGENXBIO will receive undisclosed upfront payments, ongoing fees, milestone payments and royalties on net sales of products incorporating the licensed intellectual property.

“Today’s announcement aligns with our stated goal of advancing our multiple preclinical programs during this year and into 2017 towards selection of lead clinical candidates,” said Steven Paul, M.D., President and Chief Executive Officer of Voyager Therapeutics. “Exercising the commercial options with REGENXBIO represents an important step for our preclinical pipeline programs, and we are excited with the progress of our continued collaboration with REGENXBIO.”

“These option exercises serve as further validation of our proprietary NAV Technology Platform, the breadth of our intellectual property portfolio, and the unique properties of NAV vectors for targeting the central nervous system and a number of other organ systems,” said Kenneth T. Mills, President and Chief Executive Officer of REGENXBIO. “As a leader in next-generation AAV gene therapy, REGENXBIO is pleased to continue our collaboration with Voyager and its pursuit of developing and delivering life-changing treatments for severe diseases of the CNS.”



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Corporate News, Management Comments

Related Entities

Genzyme/Sanofi-Aventis

Add Your Comment